Subcutaneous Orencia: Ph III ASTRAEA data

The double-blind, international Phase III ASTRAEA trial in 424 patients with psoriatic arthritis who had a ≥2 cm target lesion of plaque psoriasis and inadequate response or intolerance to ≥1 non-biologic DMARD showed that once-weekly 125 mg subcutaneous Orencia met the primary endpoint of improving ACR20 rate at week 24 vs. placebo (39.4% vs. 22.3%, p<0.001). Additionally, a non-significantly greater proportion of patients receiving subcutaneous Orencia achieved an HAQ response, defined as a reduction of ≥0.35 points from baseline, at week 24 vs. placebo (31% vs. 23.7%, p=0.097)...